COMPLEMENT COMPONENT C4

Primary DI

06975225463104

Basic UDI-DI Code

B-06975225463104

Reference

DTSH090707

Device Types

None provided

Regulation

Eu Ivdd

Classification

Eu Ivd General

Status

On The Market

Manufacturer

Da Te Bioengineering Technology Co., LTD.

This kit is intended for in vitro quantitative detection of complement component 4 (C4) in human serum. Complement is mainly synthesized in the liver, where the complement C3 and C4 are the most frequently detected. C4 is an important component of the classical pathway of complement activation, its determination will help SLE and other autoimmune diseases diagnosis and treatment. Autoimmune chronic active hepatitis, SLE, multiple sclerosis, rheumatoid arthritis and LgA nephropathy can lead to C4 content decrease. In SLE, C4 decreases often earlier than other complement components, and in the process of remission, C4 picks up later than other ingredients. When compared with non-lupus nephritis, C4 was significantly lower in lupus nephritis patients. The acute phase of rheumatic fever, around nodosa, dermatomyositis, myocardial infarction, Rditer’s syndrome and various types of polyarthritis can lead to C4 levels increase.

Other on-the-market devices with the same classification (Eu Ivd General) and regulation (EU IVDD).